Holen Sie sich die Stockscreener-App
11.02
0.09%
-0.010
Schlusskurs vom Vortag:
$11.03
Offen:
$11.14
24-Stunden-Volumen:
870.23K
Relative Volume:
0.58
Marktkapitalisierung:
$446.39M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-2.1481
EPS:
-5.13
Netto-Cashflow:
$-146.15M
1W Leistung:
+6.78%
1M Leistung:
-3.42%
6M Leistung:
-76.52%
1J Leistung:
-81.55%
1-Tages-Spanne:
$10.87
$11.20
1-Wochen-Bereich:
$10.33
$11.20
52-Wochen-Spanne:
$9.775
$73.00
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Vergleichen Sie KROS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.02 | 446.39M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - Defense World
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN
Institutional owners may consider drastic measures as Keros Therapeutics, Inc.'s (NASDAQ:KROS) recent US$55m drop adds to long-term losses - Simply Wall St
Research Analysts Issue Forecasts for KROS FY2028 Earnings - MarketBeat
There is no way Keros Therapeutics Inc (KROS) can keep these numbers up - SETE News
Examining the Potential Price Growth of Keros Therapeutics Inc (KROS) - Knox Daily
Leerink Partnrs Has Positive Outlook of KROS FY2028 Earnings - Defense World
(KROS) Proactive Strategies - Stock Traders Daily
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
KROS Shares Experience Surge in Value - Knox Daily
24,493 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by SG Americas Securities LLC - MarketBeat
Examining Keros Therapeutics Inc (KROS) stock is warranted - US Post News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Cantor Fitzgerald Downgrades Keros Therapeutics Inc (KROS) to a Neutral from an Overweight - Knox Daily
An analyst sees good growth prospects for Keros Therapeutics Inc (KROS) - SETE News
SG Americas Securities LLC Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Exchange Traded Concepts LLC Makes New $99,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Keros Therapeutics CEO to Speak at Biotech Conference - TipRanks
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
Exclusive: Keros CEO Reveals Next Steps in TGF-ß Innovation at Guggenheim Conference - StockTitan
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock? - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation - Markets Insider
KROS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Keros Therapeutics, Inc. and Encourages Investors to Contact the Firm - ACCESS Newswire
When (KROS) Moves Investors should Listen - Stock Traders Daily
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation - Markets Insider
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Assenagon Asset Management S.A. Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Assenagon Asset Management S.A. Sells 158,767 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on ... - The Bakersfield Californian
Keros Therapeutics seals $200M deal with Takeda - MSN
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes - MSN
Keros Therapeutics (NASDAQ:KROS) Rating Lowered to Neutral at Cantor Fitzgerald - Defense World
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS) - Business Wire
Keros Therapeutics seals $200M deal with Takeda By Investing.com - Investing.com Australia
Cantor Fitzgerald Estimates KROS FY2025 Earnings - MarketBeat
Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept - GlobeNewswire
Viridian Therapeutics sees stock soar after Phase III TED success - MSN
Cantor Fitzgerald Downgrades Keros Therapeutics (KROS) - MSN
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Keros Therapeutics Inc-Aktie (KROS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):